CClinicalTrials.gg
CompletedNCT02232750BeckmanUpdated Nov 3, 2021

Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)

An observational study in Sepsis, Severe Sepsis and Septic Shock, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Ohio State University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,320
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The investigators hypothesize that CPD parameters will provide improved prediction of sepsis compared to currently employed laboratory parameters. These studies hold the potential to shape practitioner guidelines and improve the timeliness and accuracy with which patients with sepsis are treated today.

02

Conditions studied

  • Sepsis, Severe Sepsis and Septic Shock

Browse trials for

03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's enrollment of 1,320 is above the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Emergency Department

Inclusion criteria

  • Adult (≥18 to 90 years)
  • Patients presenting to the Emergency Department
  • CBC (Complete Blood Count) with differential testing performed and CPD data retrieved

Exclusion criteria

Exclusion Criteria:

  • Previously enrolled in this study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,320 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. We are measuring CBC (complete blood count) and MNV (Mean Neutrophil Volume)

    Evaluate the clinical utility of CPD MNV as an aid in the diagnosis and risk assessment of Emergency Department patients for progression to sepsis, severe sepsis and septic shock.

    Time frame: approximately 10 months

07

Study locations

1 site
  • Wexner Medical Center at The Ohio State University
    Columbus, Ohio 43210, United States
08

References and documents

Publications

  • Crouser ED, Parrillo JE, Seymour C, Angus DC, Bicking K, Tejidor L, Magari R, Careaga D, Williams J, Closser DR, Samoszuk M, Herren L, Robart E, Chaves F. Improved Early Detection of Sepsis in the ED With a Novel Monocyte Distribution Width Biomarker. Chest. 2017 Sep;152(3):518-526. doi: 10.1016/j.chest.2017.05.039. Epub 2017 Jun 15. PubMed 28625579 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02232750
Lead sponsor
Ohio State University
Responsible party
Elliott Crouser MD (Medical Director, Intensive Care Unit, Ohio State University) — Principal investigator
First posted
Sep 5, 2014
Start date
Jul 14, 2014
Primary completion
Aug 15, 2015
Completion
Aug 15, 2015
Last update
Nov 3, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion